{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Is ResMed, Inc. technically bullish or bearish?
As of October 24, 2025, ResMed, Inc. shows a neutral technical trend with mixed signals, underperforming the S&P 500 recently, and suggesting a cautious investment approach.
Is ResMed, Inc. technically bullish or bearish?
As of October 24, 2025, ResMed, Inc. shows a neutral trend with mixed signals, as weekly indicators are mildly bearish while monthly indicators remain bullish, and the stock has underperformed the S&P 500 recently.
Is ResMed, Inc. technically bullish or bearish?
As of October 24, 2025, ResMed, Inc. has shifted to a neutral trend with mixed signals, underperforming the S&P 500 recently but showing a year-to-date return of 13.47%.
Is ResMed, Inc. overvalued or undervalued?
As of October 17, 2025, ResMed, Inc. is considered an attractive investment due to its undervaluation indicated by a P/E ratio of 36, a PEG ratio of 1.15, and a strong ROCE of 30.33%, despite recent underperformance against the S&P 500, as it has achieved a year-to-date return of 17.23%.
ResMed, Inc. Experiences Valuation Adjustment Amid Strong Financial Performance Metrics
ResMed, Inc. has recently adjusted its valuation, showcasing a P/E ratio of 36 and a price-to-book value of 8.57. Key financial metrics indicate strong operational performance, with a return on capital employed of 30.33% and return on equity of 23.58%, highlighting its competitive position in the Pharmaceuticals & Biotechnology sector.
Is ResMed, Inc. overvalued or undervalued?
As of October 17, 2025, ResMed, Inc. has an attractive valuation grade, indicating it is undervalued with a P/E ratio of 36, a PEG ratio of 1.15, and a competitive positioning among peers, despite a one-year return of 11.90% that lags behind the S&P 500's 14.08%, while outperforming year-to-date with a return of 17.23%.
ResMed, Inc. Experiences Revision in Stock Evaluation Amid Mixed Market Signals
ResMed, Inc. has recently revised its evaluation amid changing market conditions. The stock is currently priced at $281.38, reflecting a slight increase. Over the past year, it has shown significant performance variability. While it has outperformed the S&P 500 in the short term, longer-term returns remain below the index.
Is ResMed, Inc. technically bullish or bearish?
As of October 3, 2025, ResMed, Inc. has a bullish technical trend, supported by strong daily moving averages and bullish Bollinger Bands, despite some mixed signals from weekly and monthly indicators, and it has outperformed the S&P 500 year-to-date with a return of 21.82%.
Is ResMed, Inc. technically bullish or bearish?
As of October 3, 2025, ResMed, Inc. has a bullish technical trend, supported by positive daily moving averages and Bollinger Bands, despite some short-term weakness indicated by the weekly MACD and KST, while year-to-date performance shows a 21.82% return, outperforming the S&P 500's 14.18%.
Is ResMed, Inc. technically bullish or bearish?
As of September 12, 2025, ResMed, Inc. shows a mildly bullish technical trend overall, supported by bullish monthly indicators despite recent underperformance compared to the S&P 500.
Is ResMed, Inc. overvalued or undervalued?
As of July 31, 2025, ResMed, Inc. is fairly valued with a valuation grade of attractive, reflected by a P/E ratio of 36, a Price to Book Value of 8.57, and an EV to EBITDA ratio of 25.87, despite underperforming the S&P 500 in both year-to-date and five-year returns.
ResMed, Inc. Experiences Revision in Stock Evaluation Amid Mixed Market Signals
ResMed, Inc. has recently revised its market evaluation, with its stock priced at $271.19. The company has experienced significant performance fluctuations over the past year, with a notable 52-week high and low. While short-term returns lag behind the S&P 500, year-to-date performance shows resilience.
Is ResMed, Inc. technically bullish or bearish?
As of June 18, 2025, ResMed, Inc. shows a strong bullish trend supported by positive MACD, Bollinger Bands, moving averages, and KST indicators across multiple time frames.
Is ResMed, Inc. overvalued or undervalued?
As of April 23, 2025, ResMed, Inc. is rated as attractive, with a fair valuation indicated by a P/E ratio of 36, an EV to EBITDA of 25.87, and a PEG ratio of 1.15, while outperforming the S&P 500 with a 23.66% return over the past year.
Who are in the management team of ResMed, Inc.?
As of March 2022, the management team of ResMed, Inc. includes Dr. Peter Farrell (Non-Executive Chairman), Mr. Michael Farrell (CEO and Director), Mr. Ronald Taylor (Lead Independent Director), and Independent Directors Ms. Carol Burt, Mr. Jan De Witte, and Ms. Karen Drexler. They are responsible for the company's strategic direction and operations.
What does ResMed, Inc. do?
ResMed, Inc. develops and manufactures medical devices and software for respiratory disorders, with recent net sales of $1.29 billion and a market cap of $47.13 billion. Key metrics include a P/E ratio of 36.00 and a dividend yield of 2.65%.
How big is ResMed, Inc.?
As of Jun 18, ResMed, Inc. has a market capitalization of $47.13 billion, with net sales of $5.02 billion and a net profit of $1.31 billion reported over the latest four quarters.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
